Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.67 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | RB1 | P06400 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24733396 | 0.91 | DRD2 (0.74) | DRD2DRD3GRIN2BRB1DRD4 | |
| SCHEMBL5146600 | 0.84 | DRD2 (0.71) | DRD2DRD3GRIN2BRB1DRD4 | |
| Hydrochloric Acid SCHEMBL10447152 | 0.83 | DRD2 (0.61) | DRD2GRIN2BKDM1AMAOAMAOB | |
| SCHEMBL5763884 | 0.82 | DRD2 (0.54) | DRD2DRD3GRIN2BRB1DRD4 | |
| SCHEMBL5790815 | 0.81 | DRD2 (0.56) | DRD2DRD3GRIN2BRB1 | |
| SCHEMBL8074280 | 0.81 | DRD2 (0.83) | DRD2DRD3GRIN2BDRD4 | |
| SCHEMBL9862345 | 0.81 | DRD2 (0.63) | DRD2DRD3DRD4 | |
| SCHEMBL7543711 | 0.81 | DRD2 (0.83) | DRD2DRD3GRIN2BDRD4 | |
| SCHEMBL8074250 | 0.81 | DRD2 (0.83) | DRD2DRD3GRIN2BDRD4 | |
| Hydrochloric Acid SCHEMBL9063936 | 0.80 | DRD2 (0.62) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-0457883-B1 | NEW BICYCLIC AMINO-SUBSTITUTED COMPOUNDS | ASTRA AB (SE) | 1996-05-01 | — | — | EP | disclosed |
| US-5376687-A | For treatment of central nervous system disorders | AKTIEBOLAGET ASTRA (SE) | 1994-12-27 | — | — | US | disclosed |
| WO-1991009006-A1 | NEW BICYCLIC AMINO-SUBSTITUTED COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | DRD2 61/4885DRD3 56/4885GRIN2B 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.